Immune checkpoint inhibitors (ICIs) have drastically changed the clinical care of cancer.
Although cancer immunotherapy has shown promise in various types of malignancies, thus …

Immune checkpoint blockade has vastly changed the landscape of cancer treatment and
showed a promising prognosis for cancer patients. However, there is still a large portion of …

Immune checkpoint inhibitors (ICIs) have revolutionised oncology and are now standard‐of‐
care for the treatment of a wide variety of solid neoplasms. However, tumour responses …

Cancer immunotherapy has appeared as a well-known therapeutic modality for different
cancers. Yet, only a subset of patients derive clinical benefit. It is thus critical to understand …

Cancer immunotherapy has emerged as a novel and effective treatment strategy for several
types of cancer. Immune checkpoint inhibitors (ICIs) have recently demonstrated impressive …

Immune checkpoint inhibitors (ICIs), represented by anti-CTLA-4 or anti-PD-1/anti-PD-L1
pathway antibodies, have led to a revolution in cancer treatment modalities. ICIs have …

Immune checkpoint inhibitor (ICI) therapies have become the most important medical
therapies in many malignancies, such as melanoma, non-small-cell lung cancer, and …

A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …

The development of immune checkpoint inhibitors represented by PD-1 and PD-L1 has
provided new hope for the treatment of advanced cancer patients. However, there are no …

There is growing recognition that immunotherapy is likely to significantly improve health
outcomes for cancer patients in the coming years. Currently, while a subset of patients …